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MortalityIntroduction: Plasma histamine levels and D-dimer predict disease severity and mortality in advanced septic
shock. We hypothesized that increased plasma histamine levels parallel coagulation activation and yield prog-
nostic signiﬁcance already at a very early stage of bacteremia.
Patients and methods: This prospective controlled cohort study enrolled 72 consecutive non-surgical non-ICU-
ward inpatientswith newly culture-diagnosed bacteremia and a Pitt Bacteremia score ≤2 to determine the extent
of histamine and D-dimer release and their predictive role on outcome at the earliest stage of blood stream infec-
tion. Age-matched healthy adults served as internal controls (n= 36). A binominal logistic regression and a Cox
proportional hazards regression analysiswere performed to ascertain the effects of D-dimer and histamine on in-
hospital mortality.
Results: In contrast to plasma histamine, D-dimer levels were signiﬁcantly higher within hours of culture-proven
bacteremia. In-hospitalmortality occurred in 17%. Histamine levelswere neither associatedwith D-dimer level (-
r = 0.04; p N 0.05) nor with ICU admissions (r= 0.06; p N 0.05) and outcome (crude OR 0.8, 95% CI 0.3–1.9; p=
0.6). In contrast, early-elevated D-dimer levels predicted mortality: the odds to die increased with the D-dimer
level, and was 12.6 (crude OR, 95% CI 3–52; p = 0.001) in patients with a D-dimer ≥4 μg/mL (n = 13).
Conclusion: Histamine levels are elevated in only few patients (4%) with newly diagnosed bacteremia. Our ﬁnd-
ings suggest that D-dimer, but not plasma histamine, could be a promising marker of lethality already at a very
early stage of blood stream infection.
© 2015 The Authors. Published by Elsevier B.V. on behalf of European Federation of Internal Medicine. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
D-dimer is a marker of poor outcome in various critical conditions
including septic shock [1] and a component of the disseminated intra-
vascular coagulation (DIC) score of the International Society on Throm-
bosis and Haemostasis (ISTH). Coagulation activation is commonly
based on endothelial damagewith ensuing exposition of blood to extra-
vascular tissue factor.
Histamine is a classic inﬂammatory mediator with various functions
in antimicrobial host response. Among other actions, it is a potent, disseminated intravascular
nd Haemostasis; ICU, Intensive
, new oral anticoagulants; SSTI,
macology, Medical University of
tria. Tel.: +43 1 40400 29810;
a).
B.V. on behalf of European Federativasodilator [2] and increases capillary permeability. Several studies
support a detrimental effect of histamine in septic syndromes [3].
Histamine contributes to hemodynamic alterations in experimental
endotoxemia in rabbits [4] and is associated with mortality in human
sepsis [5].
Neutrophils are the critical effectors of the human innate immune
system and the ﬁrst cells recruited into sites of inﬂammation. Previous
studies showed that not merely mast cells but also neutrophils can re-
lease high amounts of histamine upon stimulation by bacterial endo-
toxins and through infection-related complement activation [6–8].
Being a potent leucocyte chemo-attractant [6], neutrophil-derived
histamine may early amplify inﬂammation, contribute to circulatory
compromise and promote organ failure in blood stream infections.
As mast cell [9] and complement activation [10] coincide with coag-
ulation activation, a link between histamine and infection-related coag-
ulopathy may be given by histamine's potency to open intercellular
tight junctions [11] with ensuing tissue factor exposure to blood and
expression [12].on of Internal Medicine. This is an open access article under the CC BY-NC-ND license
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levels over ﬁve days in patients with overt sepsis, and indicated that
histamine values on the ﬁrst daywere highest and best predicted sepsis
severity and outcome [5].
Thus, we were interested in whether increased histamine and D-
dimer levels are detected even at an earlier stage of infection and com-
pared the predictive value of both in not yet critically ill inpatients with
newly diagnosed culture-proven blood stream infection.
We hypothesized that increased plasma histamine levels parallel
coagulation activation and may yield prognostic signiﬁcance already at
a very early stage of bacteremia.
2. Patients and methods
The study protocol was approved by the local Ethics Committee and
all subjects provided oral and written informed consent. The study was
conducted in compliancewith the Declaration of Helsinki at the General
Hospital of the Medical University of Vienna, a 2100 bed tertiary care
facility, from February 2014 to February 2015.
One hundred eighteen consecutive non-surgical, non-intensive care
unit (ICU)-ward inpatients ≥18 years with fever (body temperature
≥38.3 °C) and positive bacterial blood culture or LightCycler SeptiFast
test result were screened for eligibility. Age-matched adults (n = 36)
were used as internal controls to conﬁrm the normal range of plasma
histamine levels within the study and to deﬁne the assay-speciﬁc
range of normal values. The primary outcomewas themagnitude of his-
tamine release in early bacteremia and its association with D-dimer
levels. Secondary outcomewas in-hospital mortality. Patients with ana-
phylaxis, those on histamine receptor blockers, vitamin K antagonists
(VKA) or new oral anticoagulants (NOAC), patients with advanced dis-
ease severity assessed by the Pitt Bacteremia Score (PBS N 2) and those
who underwent surgery within previous three weeks were excluded.
Study-related blood sampling was performed immediately after receipt
of positive blood-culture result. Parameters documented at time of
enrolment are shown in Table 1. The frequency of ICU admissions
was recorded and the patients were followed until hospital dis-
charge or death. Coagulation tests were performed as previously
described [13] and the ISTH DIC score was calculated as suggested
previously [14]. D-dimer levels were measured on the STA-R Evolu-
tion analyzer (Diagnostica Stago for Roche Diagnostics GmbH,
Germany; normal range b 0.5 μg/mL). Histamine EIA kits were
purchased from Immunotech (Beckmann Coulter Company; normal
range b 10 nM [nmol/L]). LightCycler SeptiFast test MGRADE (Roche
Diagnostics, Germany) and blood cultures (BacT/ALERT FA/FN plus)
were processed at the University's Department of Microbiology.
2.1. Statistical analysis
A previous study demonstrated elevated plasma histamine levels in
25% of patients with septic shock [5]. A sample size of n = 72 provided
80% power to detect elevated histamine levels in at least 5% of bacter-
emia patients. Based on a study on endocarditis patients [15], we deter-
mined a sample size of 9 patients per cohort to achieve a 90% power at
an alpha error of 2.5% to detect increased D-dimer levels in non-
survivors. Study variables are presented as absolute values (n) and rel-
ative frequencies (%), median and range (minimum to maximum) or
proportions (odds ratio, OR; hazard ratio, HR) with 95% conﬁdence in-
tervals (95% CI). Healthy volunteers were used as internal controls to
deﬁne the normal range of plasma histamine levels within the study.
Since D-dimer levels increase with advanced age [16], we used an
age-matched cohort of healthy adults, who were recruited from a vol-
unteer-databank at the Department of Clinical Pharmacology, Medical
University of Vienna.
Between-group comparisons of continuous and categorical variables
were calculated using theMann–WhitneyU test and the chi-square test.
Predeﬁned subgroups included patients with low molecular weightheparin (LMWH) prophylaxis and those with renal impairment. Corre-
lations were calculated using the Spearman rank correlation test. A
binominal logistic regression and a Cox proportional hazards regression
analysis (with mortality as dependent variable) were applied to ascer-
tain the effects of D-dimer and histamine on in-hospital mortality. The
Box–Tidwell procedure was performed to test for linearity assumption
at a signiﬁcance level of p b 0.017. Independent variableswere log trans-
formed or inversely transformed prior to analysis according to the
skewness of the distributions. The Kaplan–Meier method was used to
describe survival and the log-rank test was performed to determine dif-
ferences in the survival distributions according to the D-dimer level. Re-
garding data missing at random, only available data were analyzed.
Statistical calculations were performed with SPSS Statistical Software
Version 22.0 (Armonk, NY: IBM Corp). A two-tailed p-value b 0.05
was considered signiﬁcant.
3. Results
Of 118 consecutive bacteremia patients screened, 72were ﬁnally en-
rolled (male: 62.5%; median age: 64, range: 20–91). Remaining patients
were excluded according to the predeﬁned exclusion criteria (VKA/
NOAC therapy: n = 21, recent surgical procedure: n = 10, Pitt Bacter-
emia Score N 2: n = 9, histamine receptor blockers/anaphylaxis: n =
4). Two patients and 1 volunteer refused to participate in the study.
All included patients (100%) were followed up until hospital discharge
or death. Histamine and D-dimer levels were available for 100% of
cases. Bacteremia was veriﬁed by culture in 96% (n = 69) and by
SeptiFast test in 4% (n = 3) of patients. The median Pitt Bacteremia
Score was 1 (range: 1–2) and the median duration from blood culture
sampling to the ﬁrst positive culture result (time to blood culture posi-
tivity) and the subsequent period to study-related blood samplingwere
11.3 h (range: 2–59) and 3.5 h (range: 1–19), respectively. All patients
(100%) received antibiotic treatment upon receipt of positive blood cul-
ture result. The most frequently identiﬁed organisms were E. coli (n =
20, 28%) and S. aureus (n= 17, 24%). Table 1 shows baseline character-
istics and outcome of the study cohorts and the Supplemental
Figure gives the percentage distribution of bacteria causing blood
stream infections.
In 14% of patients no source of infection was identiﬁed (classiﬁed as
primary bacteremia). These patients had a higher rate of cancer (70% vs.
30%), more often immunosuppressive therapy (70% vs. 18%) and pre-
existing antibiotic treatment (30% vs. 13%) and had a slightly higher
rate of death (20% vs. 16%), but numberswere small in these subgroups.
Plasma histamine levels were similar between patients and healthy
controls and exceeded the normal range (i.e. N10 nM) in three patients,
who all had an uncomplicated course of disease. D-Dimer was elevated
above normal range (N0.5 μg/mL) in 68 patients (94%). Histamine levels
did not correlate with coagulation tests (ﬁbrinogen: r =−0.01, pro-
thrombin time: r =−0.04, D-dimer: r = 0.04), laboratory markers of
inﬂammation (CRP: r =−0.07, leukocytes: r = 0.12), source of infec-
tion (r = 0.19), or frequency of ICU admissions (r = 0.06; all: p N
0.05). Patients with renal impairment (n = 24, 35%) had only slightly
higher median histamine levels (2.4 nM, range: 1.0–8.9) than those
with normal kidney function (1.4 nM, range 0–15.1; p= 0.55). Prophy-
lactic anticoagulation with LMWH (40 mg enoxaparin subcutaneously
daily, n = 40, 59%) was neither associated with lower histamine
(2.3 nM, range: 1.0–15.1 vs. 1.1 nM, range: 0–10.8 in patients without
anticoagulation; p = 0.07) nor with lower D-dimer values (2.1 μg/mL,
range: 0.5–32 vs. 2.2 μg/mL, range: 0.3–27; p = 0.79).
Among all patients, in-hospital mortality occurred in 17% (n = 12).
Septic shock was the documented cause of death in 83% of non-
survivors (n = 10). The rate of both S. aureus (42% vs. 20%; p = 0.11)
and P. aeruginosa infection (17% vs. 10%; p = 0.26) was trendwise
higher in non-survivors than in survivors, while rates of E. coli infection
(17% vs. 30%; p= 0.70) were lower in those who died (Table 1, Supple-
mental Figure). Non-survivors were older (73 vs. 60 years; p = 0.03)
Table 1
Baseline characteristics and outcome of study cohorts.
Variables Volunteers
(n = 36)
Survivors
(n = 60)
Non-survivors
(n = 12)
Age (years) 64 (27–79) 60 (20–87) 73 (43–91)
Male sex 15 (42) 40 (67) 5 (42)
Comorbid diseases
Cancer 18 (30) 4 (33)
Solid 9 (15) 2 (17)
Hematologic 9 (15) 2 (17)
Cardiovascular disease 19 (32) 4 (33)
Diabetes mellitus 12 (20) 4 (33)
Chronic kidney disease 10 (17) 2 (17)
Liver cirrhosis 2 (3) 0
COPD 7 (12) 1 (8)
Immunosuppressive Therapy 13 (22) 2 (17)
CRP (mg/dL) 0.17 (0–0.5) 13.2 (0.5–41) 20 (5.5–31)
WBC (×109/L) 5.9 (4.4–10.5) 8.6 (0.01–69) 12.8 (0.04–29)
Fibrinogen (mg/dL) 325 (241–467) 604 (256–1126) 609 (191–774)
Creatinine (mg/dL) 0.9 (0.6–1.2) 1.0 (0.4–10) 1.5 (0.4–3.9)
Histamine (nmol/L) 4.3 (1–11.4) 1.7 (0–15.1) 1.8 (1–7.2)
D-dimer (μg/mL) 0.5 (0–2.8) 1.7 (0.3–6.4) 4.6 (2.8–32)
DIC score 0 2.5 (0–7) 3 (2–7)
Gram negative n.a. 36 (60) 6 (50)
Time to blood culture
positivity
n.a. 10.9 (2–59) 12.4 (3.5–31)
Source of infectiona n.a.
Primary bacteremia 8 (13) 2 (17)
Urinary tract 14 (23) 1 (8)
Respiratory tract 8 (13) 3 (25)
Abdominal 10 (17) 2 (17)
Bone 3 (5) 1 (8)
Endocarditis 3 (5) 1 (8)
CVC-associated 3 (5) 1 (8)
Soft tissue infection 11 (18) 1 (8)
Staphylococcus aureus 12 (20) 5 (42)
Escherichia coli 18 (30) 2 (17)
Pseudomonas aeruginosa 6 (10) 2 (17)
Antibiotic therapyb n.a. 54 (85) 10 (83)
LMWH n.a. 34 (57) 6 (50)
Occurrence of septic shockc n.a. 8 (13) 10 (83)
ICU admissionsd n.a. 5 (8) 9 (75)
Categorical data are presented as frequency count and percentage. Continuous variables
are expressed as median and range (minimum–maximum).
Abbreviations: COPD, chronic obstructive pulmonary diseases; CRP, C-reactive protein;
CVC, central venous catheter; DIC, disseminated intravascular coagulation; ICU, Intensive
Care Unit; LMWH, low molecular weight heparin; WBC, white blood cell count; n.a., not
applicable.
Study-related blood sampling was done 3.5 h (range: 1.0–19) after receipt of the positive
blood culture result.
a The percentage distribution of bacteria causing blood stream infections is available
with the supplement.
b Antibiotic therapy present at the time point of study-related blood sampling. All pa-
tients received antibiotic treatment upon receipt of positive blood culture result.
c Remaining two non-survivors died frommultiple organ failure due to progressing
underlying cancer (n = 1) and rupture of an aortic aneurysm (n = 1).
d One of remaining non-survivors was transferred to a palliative care clinic because of
progressive incurablemalignancy, and another patient suddenly died due to rupture of an
aortic aneurysm. Three further patients (2 survivors and 1 non-survivor)with hematolog-
ic cancer were admitted to a specialized bone marrow transplant unit upon clinical dete-
rioration, and one survivor with septic renal failure was temporarily treated at an
intermediate care unit.
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inine (1.5 vs. 1.0 mg/dL; p= 0.83) and histamine levels (1.8 vs. 1.7 nM;
p = 0.76). There was no difference in age between patients with a D-
dimer level ≥4 μg/mL and those with a D-dimer below 4 μg/mL (63 vs.
67 years; p = 0.87).
The time to blood culture positivity was similar between survi-
vors and non-survivors (10.9 vs. 12.4 h; p = 0.65). Across all
patients the time to positivity negatively correlatedwith D-dimer levels
(rho =−0.24; p = 0.06); this relationship was strongest in the sub-
group of patients with E. coli bacteremia (rho =−0.40; p = 0.07). Nocorrelation was found between time to blood culture positivity and
plasma histamine levels (rho = 0.04; p = 0.76).
Fig. 1 shows Kaplan–Meier estimates of survival stratiﬁed according
to the D-dimer level.
In a binominal logistic regression analysis the odds to die increased
with the D-dimer level, and was 12.6 (OR, 95% CI 3–52; p b 0.001;
Table 2) in patients with a D-dimer ≥4 μg/mL (n = 13). The model
(χ2 = 23; p b 0.001) correctly identiﬁed 85% of cases with a negative
predictive value of 92%. In contrast to D-dimer, histamine levels were
not associated with mortality (OR 0.8, 95% CI 0.3–1.9; p = 0.6).
Likewise, D-dimer (HR 2.5, 95% CI 1.5–4.9; p = 0.001) and age (HR
1.06, 95% CI 1.01–1.1; p = 0.017) were signiﬁcantly associated with
in-hospital mortality in univariable Cox regression analysis.
4. Discussion
Our study provides two major ﬁndings: (i) histamine levels are ele-
vated only in a few patients with early bacteremia and did not predict
outcome whereas (ii) increased D-dimer levels on the ﬁrst day of posi-
tive blood culture are predictive of in-hospital mortality.
In contrast to our results, histamine levels in sepsis were shown to
be signiﬁcantly higher in non-survivors. Unfortunately this study did
not provide any information on the frequency of end organ failure in
the limited study population of 20 patients [5]. None of our patients
had combined liver–kidney impairment, which could potentially lead
to insufﬁcient clearance of histamine levels in patients with advanced
sepsis, because both organs clear histamine very efﬁciently [17,18].
Hence, histamine levelsmay only become elevated in systemic infection
when multiple organ failure occurs, which may be addressed in future
studies.
Although previous studies report a relationship between time to
blood culture positivity and outcome [19–21], time to positivity was
not associatedwith D-dimer levels in our study. Yet, we found amoder-
ate negative correlation in the subgroup of patients with E. coli associat-
ed blood stream infection. Both the heterogeneity of bacteria causing
blood stream infections and the low sample size of our study cohort
may explain these ﬁndings.
Our study has two particular strengths. First, we investigated a ho-
mogenouspopulation of non-surgical inpatients early after onset of bac-
teremia, but without need for intensive care at the time of enrolment.
Studies on this speciﬁc population are rare compared to a vast amount
of studies on septic critical illness. Secondly, blood samples were taken
at a very early stage of disease—within 3.5 h after conﬁrmation of bac-
teremia. This may be important because readily available parameters
identifying patients with high in-hospital mortality could be of clinical
relevance andmay guide further hospital care. In this context, elevated
D-dimer levels proved to be an early marker of mortality in early
stage blood stream infection. In agreement, on-admission D-dimer
levels predict disease severity and mortality in endocarditis [15]
and critically ill patients [22] without overt DIC.
The main limitation of our study is that we used healthy volunteers
as controls. However, we hypothesized that any kind of infection-
related systemic inﬂammation will increase histamine release. There-
fore, we did not use inpatients with infection but negative blood culture
as control group. We rather decided to include only patients with clini-
cal signs of infection with culture-proven bacteremia to investigate a
homogeneous population of inpatients with ascertained bacterial
infection.
Another limitation is the relatively small sample size translating into
wide conﬁdence intervals and the low mortality rate allowing only one
independent variable to be included in the regression analysis, so that
further studies are required to conﬁrm the predictive value of D-dimer
in this population. However, the high negative predictive value is in
good agreement with the performance of D-dimer to rule out pulmo-
nary embolism [23], and a D-dimer cut-off value of 4 μg/mL is in line
with results from a study investigating the predictive value of D-dimer
Fig. 1. Kaplan–Meier curves showing survival according to the D-dimer level. Survival es-
timates were 92% for patients with D-dimer b4 μg/dL and 46% for patients with D-dimer
≥4 μg/mL, respectively. Blood samplingwas done on the day of ﬁrst positive blood culture
result.
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validity of our ﬁndings.5. Conclusions
We found increased histamine levels only in very few patients (4%)
at an early stage of blood stream infection. In contrast, elevated D-dimer
levels may be an early marker of increased mortality in non-ICU ward
inpatients with culture proven bacteremia.
Learning points:
• Studies investigating inpatients with newly diagnosed bacteremia are
rare compared to a vast amount of studies on septic critical illness.
• Our ﬁndings suggest that, in contrast to histamine, early-elevated
D-dimer levels identify bacteremia patients at high risk for in-
hospital mortality.
• D-dimer could be a promising marker of lethality in this speciﬁc
population.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ejim.2015.10.024.Table 2
Univariable binominal logistic regression analysis for in-hospital mortality.
Variables Crude OR (95% CI) P-value
Age 1.05 (1.01–1.10) 0.029
Male sex 0.36 (0.10–1.27) 0.11
CRP 1.05 (0.98–1.13) 0.17
WBC 1.03 (0.98–1.09) 0.26
Histamine 0.90 (0.67–1.20) 0.48
D-dimer ≥ 4 μg/mL 12.6 (3.03–52.35) 0.001
Platelet count 1.0 (0.99–1.01) 0.73
Renal impairment 1.54 (0.43–5.49) 0.50
Time from hospitalization to ﬁrst
blood culture result
0.57 (0.94–1.03) 0.99
Staphylococcus aureus infection 2.86 (0.77–10.6) 0.12
Escherichia coli infection 0.47 (0.09–2.35) 0.36
95% CI, 95% conﬁdence interval; CRP, C-reactive protein; OR, odds ratio;WBC, white blood
cell count. P b 0.05 was considered signiﬁcant.Contributors
BJ conceived the study. MS, MMS, HL and NB identiﬁed eligible pa-
tients, obtained oral and written informed consent and performed
study-related blood sampling. MS and BJ wrote the ﬁrst draft of the
manuscript and performed the statistical analysis. CS, HL, NB, PJS and
TB collected data and substantially drafted the manuscript.
Conﬂict of interest
The authors declare no competing interests.
Acknowledgments
This work was supported by a grant from the Austrian Science Fund
(SFB-54 grant: project number APF05404FW — Special Research
Program: Cellular Mediators Linking Inﬂammation and Thrombosis,
Medical University of Vienna). The Austrian Science Fund was neither
involved in the conduct of the study nor in the writing of the report or
in the decision to submit the article for publication.
References
[1] Gris JC, Bouvier S, Cochery-Nouvellon E, Faillie JL, Lissalde-Lavigne G, Lefrant JY.
Fibrin-related markers in patients with septic shock: individual comparison of
D-dimers and ﬁbrin monomers impacts on prognosis. Thromb Haemost 2011;
106:1228–30.
[2] Kaliner M, Sigler R, Summers R, Shelhamer JH. Effects of infused histamine: analysis
of the effects of H-1 and H-2 histamine receptor antagonists on cardiovascular and
pulmonary responses. J Allergy Clin Immunol 1981;68:365–71.
[3] Neugebauer E, Rixen D, Garcia-Caballero M, Scheid B, Lorenz W. Time sequence of
histamine release and formation in rat endotoxic shock. Shock 1994;1:299–306.
[4] Matsuda N, Hattori Y, Sakuraya F, Kobayashi M, Zhang XH, Kemmotsu O, et al. He-
modynamic signiﬁcance of histamine synthesis and histamine H1- and H2-
receptor gene expression during endotoxemia. Naunyn Schmiedebergs Arch
Pharmacol 2002;366:513–21.
[5] Neugebauer E, Lorenz W, Rixen D, Stinner B, Sauer S, Dietz W. Histamine release in
sepsis: a prospective, controlled, clinical study. Crit Care Med 1996;24:1670–7.
[6] Alcaniz L, Vega A, Chacon P, El Bekay R, Ventura I, Aroca R, et al. Histamine produc-
tion by human neutrophils. FASEB J Off Publ Fed Am Soc Exp Biol 2013;27:2902–10.
[7] Xu X, Zhang D, Zhang H, Wolters PJ, Killeen NP, Sullivan BM, et al. Neutrophil hista-
mine contributes to inﬂammation in mycoplasma pneumonia. J Exp Med 2006;203:
2907–17.
[8] Norn S, Jensen C, Dahl BT, Stahl Skov P, Baek L, Permin H, et al. Endotoxins release
histamine by complement activation and potentiate bacteria-induced histamine re-
lease. Agents Actions 1986;18:149–52.
[9] Asero R, Tedeschi A, Riboldi P, Grifﬁni S, Bonanni E, Cugno M. Severe chronic urticar-
ia is associated with elevated plasma levels of D-dimer. Allergy 2008;63:176–80.
[10] Cugno M, Cicardi M, Bottasso B, Coppola R, Paonessa R, Mannucci PM, et al. Activa-
tion of the coagulation cascade in C1-inhibitor deﬁciencies. Blood 1997;89:3213–8.
[11] Gardner TW, Lesher T, Khin S, Vu C, Barber AJ, Brennan Jr WA. Histamine reduces
ZO-1 tight-junction protein expression in cultured retinal microvascular endothelial
cells. Biochem J 1996;320(Pt 3):717–21.
[12] Steffel J, Arnet C, Akhmedov A, Iseli SM, Luscher TF, Tanner FC. Histamine differen-
tially interacts with tumor necrosis factor-alpha and thrombin in endothelial tissue
factor induction: the role of c-Jun NH2-terminal kinase. J Thromb Haemost: JTH
2006;4:2452–60.
[13] Schwameis M, Thaler J, Schober A, Schorgenhofer C, Kulinna-Cosentini C, Laggner A,
et al. Tranexamic acid and ﬁbrinogen restore clotting in vitro and in vivo in cardiac
thrombus associated hyperﬁbrinolysis with overt bleedings. Thromb Haemost 2014;
112:1071–5.
[14] Taylor Jr FB, Toh C-H, Hoots WK, Wada H, Levi M. Scientiﬁc Subcommittee on Dis-
seminated Intravascular Coagulation (DIC) of the International Society on Thrombo-
sis and Haemostasis (ISTH). Towards deﬁnition, clinical and laboratory criteria, and
a scoring system for disseminated intravascular coagulation, Thromb Haemost
2001;86:1327–30.
[15] Turak O, Canpolat U, Ozcan F, Yayla C, Mendi MA, Oksuz F, et al. D-dimer level pre-
dicts in-hospital mortality in patients with infective endocarditis: a prospective
single-centre study. Thromb Res 2014;134:587–92.
[16] Sohne M, Kamphuisen PW, van Mierlo PJ, Buller HR. Diagnostic strategy using a
modiﬁed clinical decision rule and D-dimer test to rule out pulmonary embolism
in elderly in- and outpatients. Thromb Haemost 2005;94:206–10.
[17] Helander CG, Lindell SE, Westling H. The renal removal of C-14-labelled histamine
from the blood in man. Scand J Clin Lab Invest 1965;17:524–8.
[18] Lindell SE,Westling H. The hepatic removal of 14C-histamine from the blood inman.
Scand J Clin Lab Invest 1966;18:268–72.
[19] Khatib R, Riederer K, Saeed S, Johnson LB, Fakih MG, Sharma M, et al. Time to posi-
tivity in Staphylococcus aureus bacteremia: possible correlation with the source and
786 M. Schwameis et al. / European Journal of Internal Medicine 26 (2015) 782–786outcome of infection. Clinical Infectious Diseases: An Ofﬁcial Publication of the
Infectious Diseases Society of America, 41; 2005 594–8.
[20] Kim J, Gregson DB, Ross T, Laupland KB. Time to blood culture positivity in Staphylo-
coccus aureus bacteremia: association with 30-day mortality. J Infect 2010;61:
197–204.
[21] WillmannM, Kuebart I, Vogel W, Flesch I, Markert U, Marschal M, et al. Time to pos-
itivity as prognostic tool in patients with Pseudomonas aeruginosa bloodstream in-
fection. J Infect 2013;67:416–23.[22] Shorr AF, Trotta RF, Alkins SA, Hanzel GS, Diehl LF. D-Dimer assay predicts mortality
in critically ill patients without disseminated intravascular coagulation or venous
thromboembolic disease. Intensive Care Med 1999;25:207–10.
[23] Di Nisio M, Sohne M, Kamphuisen PW, Buller HR. D-Dimer test in cancer patients
with suspected acute pulmonary embolism. J Thromb Haemost: JTH 2005;3:
1239–42.
